<DOC>
	<DOCNO>NCT01433016</DOCNO>
	<brief_summary>The Exalenz clinical investigation multicenter , non-randomized , study ¹³C-Octanoate Breath Test ( OBT ) . The present study feasibility trial , aim evaluate capability OBT measurement differentiate presence absence HCC determine Magnetic Resonance Imaging ( MRI ) patient chronic liver disease .</brief_summary>
	<brief_title>Detection Hepatocellular Carcinoma ( HCC ) With Octanoate Breath ID Test Compared MRI</brief_title>
	<detailed_description>The Octanoate Breath Test ( OBT ) develop Exalenz perform BreathID System consist BreathID device test kit contain nasal cannula , calibration gas container non-radioactive isotope ¹³C- Octanoate solution , measure computes ratio ¹³CO2 12CO2 patient 's exhaled breath . This study 's aim provide data novel system dynamically accurately assess liver function bed side . It hop system provide prognostic information faster achieve present traditional method . It hypothesize future OBT may impact decision make clinical practice group HCC patient , allow great chance proper management hence survival .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Any patient chronic liver disease risk HCC . Age &gt; 18 year . Patient MRI result ( positive negative HCC ) 3 month prior recruitment schedule MRI trial period . Patient naïve HCC treatment . Underwent RFA TACE Oral HCC treatment . Portal vein thrombosis . Prior TIPS placement . Severe congestive heart failure ( LVEF echocardiogram &lt; 20 % ) . Severe pulmonary hypertension ( By echocardiogram , PAS &gt; 45 mmHg ) . Uncontrolled diabetes mellitus ( HBA1C &gt; 9.5 % ) . Any autoimmune disorder , currently treat prednisone immune suppressive medication . Previous surgical bypass surgery morbid obesity ( BMI &gt; 45 ) . Extensive small bowel resection . Patients currently receive total parenteral nutrition contraindication oral drug . Women pregnant breast feeding . Patients acute current exacerbation chronic obstructive pulmonary disease bronchial asthma . Patient take drug interfere octanoate metabolism also cause NAFLD independent metabolic syndrome , include : corticosteroid , amiodarone , tetracycline , valproic acid , methotrexate , stavudine , zidovudine . Patient , base opinion investigator , enrol study . Patient unable unwilling sign inform consent . Patients participate clinical trial evaluate experimental treatment procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>HCC Hepatocellular carcinoma</keyword>
	<keyword>OBT Octanoate Breath Test</keyword>
</DOC>